96 Tests PN: A111410

Components:

45x Ab-conjugated beads (S4P8 - human IL-28A Ab-bead). PN: B111410A. One vial containing 100 µL of anti-human IL-28A conjugated to AimPlex Bead S4P8.

25x Biotin-detection Ab ((human IL-28A Biotin-dAb). PN: B111410B. One vial containing 100 µL of biotinylated anti-human IL-28A.

Lyophilized Standard Mix-Human Group 2 Panel B, 10-Plex. PN: HG20010. One vial containing lyophilized recombinant human IL-17F, IL-20, IL-21, IL-28A, IL-29, IL-33, M-CSF, MPO, TSLP, and VEGF-A. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

Application: Optimal antibody pair and antigen standard for assaying human IL-28A.  Can be multiplexed with other analytes in Human Group 2.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 2: Negligible

  • Sample volume: 15 µL/test

Description:

Interleukin-28A (Accession Q8IZJ0) is one of three members of the IFN-λ subfamily within the IL-10 cytokine family. The others being IL-29 (IFN-λ1) and IL-28B (IFN-λ3), all also known as the Interferon III family. IL-28A is involved in adaptive immune responses as an antiviral cytokine that primarily targets epithelial cells and hepatocytes. It may play an important role in the health of the dermis and in responding to viral and microbial infections. Increased expression of IL-28A and its receptor Il-28AR1 have been detected in patients with invasive urothelial carcinoma, it is currently understood to induce migration of bladder cancer cells.

References:

  1. Lee S et al. Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-κB-mediated MMP-9 expression inducing the MAPK pathway. Cellular Signalling. 2012; 24(9): 1734-1742. Doi: 10.1016/j.cellsig.2012.04.013.

  2. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: Promising cytokines with type I interferon-like properties. Cytokine & Growth Factor Reviews. 2010; 21(4): 237-251. Doi: 10.1016/j.cytogfr.2010.04.002.

  3. Wolk K et al. Interleukin-28 and Interleukin-29: Novel Regulators of Skin Biology. J Interferon & Cytokine Res. 2010; 30(8). Doi: 10.1089/jir.2010.0064.